復發性呼吸道乳頭狀瘤病（RRP）：市場展望、流行病學、競爭格局和市場預測報告，2025-2035年

市場概覽

• 由於以下因素，RRP市場預計將以中等至較高的複合年成長率（5-7%）成長：
• 診斷數量和認知度均有所提升。
• 新興免疫療法的傳播
• 治療需求源於高復發率
• 市場仍以手術和輔助性治療主導，現有的支持和輔助性治療佔超過 70-75%。
• 成人市場佔銷售額的大部分（65-70%），這得益於更高的治療強度以及聯合治療和輔助性治療。
• 預計到 2035 年，新興治療方法將佔 20-30% 的市場佔有率，並以兩位數的複合年成長率成長。

復發性呼吸道乳頭狀瘤病變（RRP）概述

復發性呼吸道乳頭狀瘤病（RRP）是一種罕見且嚴重的病毒性疾病，由人類乳突病毒（HPV）6型和11型引起，其特徵是良性但阻塞性乳頭狀瘤持續生長，主要發生於喉部。此病有兩種臨床表現：一種進行性的青少年發病型（JoRRP），主要透過母嬰垂直傳播；另一種是進展相對緩慢但持續致殘的成人發病型（AoRRP）。

臨床上，進行性呼吸道乳頭狀瘤病（RRP）會導致進行性氣道阻塞、發聲困難、喘息和反覆呼吸衰竭，通常需要多次手術干預以維持氣道通暢。由於病毒持續存在於上皮細胞中，此病呈現慢性復發性病程，部分患者每年需進行多次手術。

傳統的標準治療方法是反覆進行手術減重，雖然這種方法能有效控制症狀，但眾所周知，它會給患者帶來極大的負擔，並且與長期氣道損傷有關。然而，治療模式正在改變：

• 由於HPV疫苗的廣泛使用，青少年復發性氣道狹窄的發生率正在下降。
• 對於病情嚴重和難治性病例，標靶輔助性治療，特別是抗 VEGF 藥物（如Bevacizumab），正在增加，以減少手術次數並維持氣道完整性。

儘管取得了這些進展，但目前尚未建立根治性治療方法，復發性呼吸道乳頭狀瘤病（RRP）仍然是一種亟需治療的疾病。因此，人們對緩解疾病修飾性免疫療法和治療性疫苗寄予厚望。

主要亮點

• RRP 患者數量仍然很少，但正在穩定增加（年均複合成長率 1-2%），成人發病病例的比例高於青少年發病病例（65-70%）。
• HPV 6 型和 11 型佔病例的 85-90%，凸顯了病毒的強致病性，並強調了以疫苗為基礎的策略的重要性。
• 此疾病的負擔主要取決於復發的頻率，而不是發病率，尤其是在青少年復發性重組手術（JoRRP）病例中，患者每年需要多次手術。
• 目前的治療狀況較為分散，嚴重依賴輔助性治療，其特徵如下：
• 過度使用抗病毒藥物和COX抑制劑（成人使用率達60-80%）
• 根據疾病的嚴重程度，免疫調節藥物和類視色素的使用程度為中等（25-70%）。
• 成年患者的治療使用率始終高於兒童患者，這反映出成年患者的治療強度更高，合併症負擔更重。
• 隨著新治療方法（例如治療性人類乳突病毒(HPV)疫苗和免疫腫瘤藥物）的出現，預計未來治療將從程序性方法轉向緩解疾病方法。

格式化和更新訊息

• 詳細報告（PDF）
• 市場預測模型（基於微軟Excel）
• 流行病學數據（MS Excel，互動式工具）
• 高階主管洞察（PPT簡報）
• 其他功能：定期更新、自訂和顧問支援。
• 根據 Thelansis 的政策，我們確保所有最新更新在發布前都反映在報告內容和市場模型中。

主要問題

• 如何最佳化 G8 市場（美國、歐盟 5 國、日本、中國）的藥物開發與生命週期管理策略？
• 從發病率、盛行率、人群組成以及接受藥物治療的患者人數來看，患者數量分別是多少？
• 未來十年市場收入和病患佔有率的預測是多少？
• 哪些因素對市場趨勢影響最大？
• 受訪專家對目前和新興的治療方法有何看法？
• 哪款在研發線產品最有前景？其上市潛力及未來市場定位如何？
• 主要未被滿足的需求是什麼？ KOL 對目標受眾有何期望？
• 為確保藥物核准並順利進入市場，必須滿足哪些關鍵的監管和支付方要求？

目標國家

• G8
  • 美國
  • EU5
    • 法國
    • 德國
    • 義大利
    • 西班牙
    • 英國
  • 日本
  • 中國

大公司

• Precigen, Inc.
• Inovio Pharmaceuticals
• Eisai Inc.
• Merck Sharp &Dohme

目錄

第1章：主要調查結果及分析師說明

• 主要趨勢：市場概況、SWOT分析、商業性利益與風險等。

第2章：疾病背景

• 疾病定義、分類、病因和病理生理學、藥物標靶等。

第3章：流行病學

• 重點
• 發病率/盛行率
• 已確診並接受藥物治療的患者人數
• 合併症
• 其他相關患者群

第4章 市場規模及預測

• 重點
• 市場促進因素與限制因素
• 按藥物分類的趨勢
• 各國具體趨勢

第5章 競爭情勢

• 目前的治療方法
  • 重點
  • 診斷和治療過程/演算法
  • 主要治療方法概述及KOL洞察
• 新興治療方法
  • 重點
  • 值得關注的後期新治療方法－概述、市場上市預期及KOL洞察
  • 值得關注的早期研發管線

第6章：未滿足的需求與目標產品分析

• 主要未滿足的需求以及透過新興治療方法實現的未來可能性
• TPP分析與KOL展望

第7章 監理與報銷環境

第8章附錄

Recurrent Respiratory Papillomatosis (RRP) Market Outlook

Thelansis's "Recurrent Respiratory Papillomatosis (RRP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Recurrent Respiratory Papillomatosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Recurrent Respiratory Papillomatosis (RRP) Overview

Recurrent respiratory papillomatosis (RRP) is a rare, highly morbid viral disease driven by human papillomavirus (HPV) genotypes 6 and 11, characterized by the relentless growth of benign yet obstructive papillomas, primarily in the larynx. The disease manifests in two clinical forms: a more aggressive juvenile-onset variant (JoRRP), typically acquired via vertical transmission, and an adult-onset form (AoRRP) with relatively slower progression but sustained morbidity.

Clinically, RRP leads to progressive airway obstruction, voice impairment, stridor, and recurrent respiratory compromise, often necessitating repeated surgical interventions to maintain airway patency. Due to viral persistence within epithelial cells, the disease follows a chronic relapsing course, with some patients requiring multiple procedures annually.

The traditional standard of care has been repetitive surgical debulking, which, while effective in symptom control, is associated with significant procedural burden and long-term airway damage. However, the treatment paradigm is evolving:

• Widespread prophylactic HPV vaccination is contributing to a declining incidence of juvenile RRP
• Targeted adjuvant therapies, particularly anti-VEGF agents such as bevacizumab, are increasingly used in severe or recalcitrant cases to reduce surgical frequency and preserve airway integrity

Despite these advances, there remains no definitive curative therapy, positioning RRP as a high unmet-need disease with strong momentum toward disease-modifying immunotherapies and therapeutic vaccines.

Key Highlights

• The RRP patient population remains small but steadily growing (1-2% CAGR), with adult-onset cases contributing a larger share (65-70%) compared to juvenile cases.
• HPV 6 and 11 collectively account for 85-90% of cases, reinforcing the strong viral etiology and relevance of vaccine-based strategies.
• Disease burden is driven more by recurrence frequency rather than incidence, with patients requiring multiple surgical interventions annually, especially in JoRRP.
• Current treatment landscape is fragmented and adjunctive-heavy, with:
• High utilization of antivirals and COX inhibitors (60-80% usage in adults)
• Moderate use of immunomodulators and retinoids (25-70%) depending on disease severity
• Adult patients show consistently higher therapy utilization rates vs pediatric, reflecting greater treatment intensity and comorbidity burden.
• Emerging therapies (e.g., therapeutic HPV vaccines and immuno-oncology agents) are expected to shift treatment from procedural to disease-modifying approaches over time.

Market Overview

• The RRP market is expected to grow at a moderate-to-high CAGR (5-7%), driven by:
• Increasing diagnosis and awareness
• Uptake of emerging immunotherapies
• High recurrence-driven treatment demand
• The market remains procedure- and adjunct-therapy driven, with >70-75% contribution from existing supportive and adjunct therapies
• Adult segment dominates revenue (65-70%), supported by higher treatment intensity and greater use of combination/adjuvant therapies
• Emerging therapies are projected to capture 20-30% market share by 2035 & grow at double-digit CAGR

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Precigen, Inc.
• Inovio Pharmaceuticals
• Eisai Inc.
• Merck Sharp & Dohme

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)